disease modifying treatments
PreclinicalSmall molecule
disease modifying treatments is one of 28 small molecule programs targeting Spinal Muscular Atrophy. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Spinal Muscular Atrophy
#DrugCompanyPhaseTrials
1Evrysdi
RocheApproved
Spinraza
BiogenPhase 3
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Amondys 45
Sarepta TherapeuticsApproved
Depakote
AbbViePhase 2
Droxia
TTheravia
Phase 2
Celebrex
PPhiladelphia Eye Associates
Phase 2
Rilutek
AAzurity Pharmaceuticals
Phase 2
Onasemnogene Abeparvovec
NovartisPhase 3
RO7204239
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details